SMS Pharmaceuticals Limited (SMSPHARMA.BO)
INR 242.45
(2.08%)
INR 242.45
(2.08%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 833.64 Million INR | 298.8% |
| 2022 | 213.39 Million INR | -72.98% |
| 2021 | 789.84 Million INR | -19.13% |
| 2020 | 976.68 Million INR | 81.07% |
| 2019 | 539.39 Million INR | -20.83% |
| 2018 | 681.27 Million INR | -5.59% |
| 2017 | 721.58 Million INR | 35.16% |
| 2016 | 533.85 Million INR | 162.61% |
| 2015 | 203.28 Million INR | -75.72% |
| 2014 | 837.38 Million INR | 88.72% |
| 2013 | 443.7 Million INR | 129.36% |
| 2012 | -1.51 Billion INR | -2187.93% |
| 2011 | 72.38 Million INR | -72.88% |
| 2010 | 266.87 Million INR | -15.68% |
| 2009 | 316.49 Million INR | -9.97% |
| 2008 | 351.52 Million INR | -32.86% |
| 2007 | 523.57 Million INR | 10.58% |
| 2006 | 473.48 Million INR | 85.5% |
| 2005 | 255.24 Million INR | 21.46% |
| 2004 | 210.13 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 251.29 Million INR | -2.22% |
| 2023 Q1 | 184.92 Million INR | 21.16% |
| 2023 Q4 | 257.01 Million INR | 22.45% |
| 2023 FY | 851.03 Million INR | 298.8% |
| 2023 Q3 | 209.88 Million INR | 5.36% |
| 2023 Q2 | 199.21 Million INR | 7.73% |
| 2022 Q4 | 152.63 Million INR | 46.91% |
| 2022 FY | 213.39 Million INR | -72.98% |
| 2022 Q1 | -87.43 Million INR | 29.57% |
| 2022 Q2 | 54.69 Million INR | 162.55% |
| 2022 Q3 | 103.89 Million INR | 89.97% |
| 2021 Q3 | 189.49 Million INR | -51.04% |
| 2021 FY | 789.84 Million INR | -19.13% |
| 2021 Q2 | 387.05 Million INR | 6.21% |
| 2021 Q1 | 364.43 Million INR | 2.5% |
| 2021 Q4 | -124.14 Million INR | -165.51% |
| 2020 Q1 | 167.6 Million INR | 59.06% |
| 2020 Q2 | 189.74 Million INR | 13.21% |
| 2020 FY | 976.68 Million INR | 81.07% |
| 2020 Q3 | 296.91 Million INR | 56.48% |
| 2020 Q4 | 355.53 Million INR | 19.74% |
| 2019 Q3 | 154.28 Million INR | -11.4% |
| 2019 FY | 539.39 Million INR | -20.83% |
| 2019 Q2 | 174.14 Million INR | -7.16% |
| 2019 Q1 | 187.56 Million INR | 68.88% |
| 2019 Q4 | 105.36 Million INR | -31.71% |
| 2018 Q1 | 193.13 Million INR | 0.0% |
| 2018 FY | 681.27 Million INR | -5.59% |
| 2018 Q4 | 111.06 Million INR | -48.0% |
| 2018 Q3 | 213.6 Million INR | -2.88% |
| 2018 Q2 | 219.94 Million INR | 13.88% |
| 2017 FY | 721.58 Million INR | 35.16% |
| 2016 FY | 533.85 Million INR | 162.61% |
| 2016 Q1 | 182.04 Million INR | -3.89% |
| 2016 Q2 | 228.01 Million INR | 25.25% |
| 2015 Q2 | 180.06 Million INR | 31.66% |
| 2015 FY | 203.28 Million INR | -75.72% |
| 2015 Q4 | 189.4 Million INR | -12.85% |
| 2015 Q3 | 217.32 Million INR | 20.69% |
| 2015 Q1 | 136.76 Million INR | -49.65% |
| 2014 Q3 | 301.46 Million INR | 146.6% |
| 2014 Q2 | 122.24 Million INR | -13.94% |
| 2014 FY | 837.38 Million INR | 88.72% |
| 2014 Q1 | 142.04 Million INR | -16.76% |
| 2014 Q4 | 271.62 Million INR | -9.9% |
| 2013 Q1 | 1.73 Million INR | -99.64% |
| 2013 Q4 | 170.65 Million INR | -2.33% |
| 2013 FY | 443.7 Million INR | 129.36% |
| 2013 Q3 | 174.72 Million INR | 82.0% |
| 2013 Q2 | 96 Million INR | 5439.87% |
| 2012 Q4 | 484.65 Million INR | 582.32% |
| 2012 Q1 | 29.47 Million INR | -41.28% |
| 2012 Q2 | -107.92 Million INR | -466.1% |
| 2012 FY | -1.51 Billion INR | -2187.93% |
| 2012 Q3 | -100.48 Million INR | 6.89% |
| 2011 FY | 72.38 Million INR | -72.88% |
| 2011 Q4 | 50.19 Million INR | -29.97% |
| 2011 Q3 | 71.67 Million INR | 0.0% |
| 2010 FY | 266.87 Million INR | -15.68% |
| 2009 FY | 316.49 Million INR | -9.97% |
| 2008 FY | 351.52 Million INR | -32.86% |
| 2007 FY | 523.57 Million INR | 10.58% |
| 2006 FY | 473.48 Million INR | 85.5% |
| 2005 FY | 255.24 Million INR | 21.46% |
| 2004 FY | 210.13 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott India Limited | 13.79 Billion INR | 93.956% |
| Cipla Limited | 105.7 Billion INR | 99.211% |
| Gland Pharma Limited | 9.9 Billion INR | 91.586% |
| GlaxoSmithKline Pharmaceuticals Limited | 13.6 Billion INR | 93.871% |
| Kopran Limited | 615.26 Million INR | -35.494% |
| Marksans Pharma Limited | 7.79 Billion INR | 89.301% |
| NGL Fine-Chem Limited | 416.27 Million INR | -100.265% |
| Pfizer Limited | 9.61 Billion INR | 91.327% |
| Sanofi India Limited | 7.79 Billion INR | 89.311% |